



Review

Magnetic Nanomaterials for Arterial Embolization and Hyperthermia of Parenchymal Organs Tumors: A Review

Natalia E. Kazantseva ^{1,2,*}, Ilona S. Smolkova ¹, Vladimir Babayan ¹, Jarmila Vilčáková ^{1,2} , Petr Smolka ¹ and Petr Saha ^{1,2}

¹ Centre of Polymer Systems, Tomas Bata University in Zlín, Třída Tomáše Bati 5678, 760 01 Zlín, Czech Republic; smolkova@utb.cz (I.S.S.); babayan@utb.cz (V.B.); vilcakova@utb.cz (J.V.); smolka@utb.cz (P.S.); saha@utb.cz (P.S.)

² Polymer Centre, Faculty of Technology, Tomas Bata University in Zlín, Vavrečkova 275, 760 01 Zlín, Czech Republic

* Correspondence: kazantseva@utb.cz; Tel.: +420-608607035

Abstract: Magnetic hyperthermia (MH), proposed by R. K. Gilchrist in the middle of the last century as local hyperthermia, has nowadays become a recognized method for minimally invasive treatment of oncological diseases in combination with chemotherapy (ChT) and radiotherapy (RT). One type of MH is arterial embolization hyperthermia (AEH), intended for the presurgical treatment of primary inoperable and metastasized solid tumors of parenchymal organs. This method is based on hyperthermia after transcatheter arterial embolization of the tumor's vascular system with a mixture of magnetic particles and embolic agents. An important advantage of AEH lies in the double effect of embolotherapy, which blocks blood flow in the tumor, and MH, which eradicates cancer cells. Consequently, only the tumor undergoes thermal destruction. This review introduces the progress in the development of polymeric magnetic materials for application in AEH.

Keywords: magnetic hyperthermia; arterial embolization hyperthermia; magnetic nanoparticles; embolic agents; animal model; clinical application (results)



Citation: Kazantseva, N.E.; Smolkova, I.S.; Babayan, V.; Vilčáková, J.; Smolka, P.; Saha, P. Magnetic Nanomaterials for Arterial Embolization and Hyperthermia of Parenchymal Organs Tumors: A Review. *Nanomaterials* **2021**, *11*, 3402. <https://doi.org/10.3390/nano11123402>

Academic Editor: Joachim Clement

Received: 12 November 2021

Accepted: 8 December 2021

Published: 15 December 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Cancer is the second leading cause of death around the world. According to the World Health Organization statistics report, 19.3 million new cancer cases were diagnosed worldwide, with almost 10 million deaths from cancer in 2020 [1]. It is also notable from this report that the number of deaths due to cancer does not change from year to year, notwithstanding the application of new drugs and combination treatments. Moreover, the number of cancer patients is expected to rise to almost 30 million annually by 2040 (Figure 1).




Figure 1. Projected number of new cancer cases in 2040 according to the 4-Tier Human Development Index. Source: GOBOCAN 2020. Reprinted with permission [1]. Copyright 2021, John Wiley, and Sons.

New approaches to cancer detection and treatment are needed. The current tendency in oncology is focused on the complex palliative therapy in treating cancer patients. One of such methods is Hyperthermia (HT) combined with RT and ChT, standardized by different organizations such as Radiation Oncology Group, European Society for Hyperthermic Oncology, and others [2–5]. Hyperthermia in oncology refers to the treatment of malignant diseases by controlled heating between 39–45 °C for a period of time with minimal unwanted side effects. Depending on tumor location and tissue volume, conventional HT is subdivided into three categories: local, locoregional, and whole-body [5,6]. Local hyperthermia aims to increase the temperature of near-surface primary malignant tumors before the metastases stage by ultrasound, electroporation, and more often by converting electromagnetic energy into heat. Locoregional hyperthermia is useful for large inoperable deep-seated tumors and is based on perfusion of organ and body with heated fluids or electromagnetic energy. Whole-body hyperthermia is used for patients with solid metastatic tumors. This type of hyperthermia is based on heating the blood in extracorporeal circulation using infrared radiation, hot water blankets, or thermal chambers. The medical hyperthermia devices using electromagnetic waves are called applicators. According to the heating principle, applicators are principally divided into dielectric applicator systems (capacitive heating applicator) and inductive heating systems (inductive heating applicators). A detailed description of HT technology currently used in clinical practice is presented in a book by Andre Vander Vorst [7] and review articles by H. Petra Kok et al. [8] and H. Dobšiček Trefna et al. [9].

Hyperthermia in combination with RT and ChT is widely used in Europe, the United States, Japan, China, Russia, and other countries for the treatment of different tumor types and sites: mammary gland, prostate gland, lung, liver, intestinal tract, bone tissue, glioblastoma, etc. [9–21]. Preclinical *in vitro* and *in vivo* studies have shown two aspects of cancer inhibition by combining HT with RT and ChT: the death of individual cells from hyperthermia and enhancing the effects of RT and ChT [15]. The additional benefit of HT in combination with RT and ChT has been shown in a number of randomized clinical trials. Thus, for example, the overall response rate increased from 38% to 60% for patients with breast cancer who received HT + RT, while the treatment of cervical cancer at stage IIB-III-IVA with a combination of RT, ChT, and HT showed improved complete response rates and significantly increased overall survival [16,17]. Combining these methods has also proven to be effective in the preoperative treatment of stage III lung cancer [19]. According to the results obtained, the overall response to treatment was about 94%, including a complete response of about 22% and a partial response of about 72%. The significant regression of the tumor achieved in the preoperative period makes it possible to reduce the volume of surgical treatment and thereby facilitate the course of the postoperative period.

Currently, hyperthermia's cellular and molecular basis and its effect on cancer treatment in combination with RT and ChT are better understood due to the substantial technical improvement in the sources used to supply heat and measure its output. Depending on the applied temperature and duration of treatment, various biological effects of hyperthermia on macroscopic and microscopic levels have been revealed [18,22,23].

The dominant mechanisms of cancer cell death caused by heating tissues to a temperature within the range of 41–45 °C are necrosis, apoptosis, and modes related to mitotic catastrophe [24–28]. The macroscopic effect of hyperthermia manifests itself in the tumor's vascular system, i.e., heat increases the blood flow, which increases the vessel permeability and tissue oxygenation, which, in turn, causes a temporarily increased radiosensitivity. Concerning the microscopic effect, hyperthermia causes changes in the cellular components of the tumor and thus leads to a loss of cellular homeostasis. The mechanisms involved in heat-induced cell damage are protein denaturation, lipid peroxidation, and DNA damage. Moreover, hyperthermia modulates the immune system due to the production of heat shock proteins (HSPs), which, in turn, stimulates macrophages by acting in damage-associated molecular patterns. On the other hand, HSPs protect cells from apoptosis, which reduces the effect of hyperthermia.

The chemo-sensitizing property of hyperthermia is determined by (1) an increase in the cellular membrane permeability so that chemotherapeutic drugs can more easily pass the cell barrier, (2) a drug-induced DNA adduct formation, and (3) inhibition of DNA repair, which all enhance the cytotoxic activity of drugs [14,27]. Moreover, intratumoral heat affects DNA damage pathways by deactivating specific repair proteins. These processes are highly dependent on several factors: the degree of temperature elevation, the duration of heat, and the cell type and microenvironmental conditions, such as the acidity and oxygenation status of the tumor. In addition, hyperthermic chemosensitization depends on the type and concentration of drugs due to different mechanisms by which heat affects drug activity, i.e., transport, intracellular cytotoxicity, and metabolism. In vivo and in vitro studies, as well as clinical results, have demonstrated that most chemotherapeutic drugs are effective when delivered just before or during an HT session [28].

Critical problems of conventional hyperthermia in clinical practice are insufficient heat localization in the tumor, especially in deep-seated tumors, heterogeneity in temperature distribution within the tumor, and overheating of healthy tissues due to deficiency in temperature monitoring. For these reasons, the use of hyperthermia alone gives an overall response of only about 15% [5]. The main challenge of hyperthermia is to achieve a precise energy delivery and controlled heating of primary and metastasized tumors while avoiding heating of normal tissues and overcoming the thermotolerance [26]. In particular, MH proposed in 1957 by R.K. Gilchrist as local hyperthermia [29] is still undergoing preclinical and clinical trials as an independent method for cancer therapy and as a multimodal treatment in combination with RT and ChT [30–38]. The general methodology of MH comprises the introduction of magnetic material into the tumor followed by exposure to an alternating magnetic field (AMF) at moderate frequencies and amplitudes ($f = 0.05\text{--}1.5$ MHz, $H \leq 15$ kA·m⁻¹) to limit peripheral nerve stimulation due to induced eddy currents occurring in the body [39–41]. The free current loss also needs to be considered since it may lead to nonspecific induction heating. The heating ability of magnetic material in AMF is usually estimated by specific power loss (SLP) or specific absorption rate (SAR), which are defined as heating power (P [W]) generated per unit mass of magnetic nanoparticles (m_{MNP} [g]): $\text{SAR} = P/m_{\text{MNP}}$ [42,43]. The heating power produced by the mediator depends on nanoparticles (NPs) concentration, core size, and magnetic properties (saturation magnetization, magnetic anisotropy energy), the viscosity and heat capacity of dispersion media, as well as on the extrinsic factors, i.e., frequency and amplitude of AMF [7]. To eliminate these extrinsic factors, intrinsic loss power (ILP) as a system-independent parameter was introduced to compare results obtained in different field conditions: $\text{ILP} = \text{SAR}/f \times H^2$ [44].

The key requirement in MH is maximizing heat generation within medically safe limits of the AMF. Therefore, particle size and particle size distribution must be taken under control. Experimental determination of the heating effect of magnetic materials is usually conducted by the nonadiabatic calorimetric method [45] and rarely by adiabatic calorimetry [46]. It is also possible to predict the size-dependent heating efficiency of MNPs by stochastic Neel–Brown Langevin equation and Monte Carlo (MC) simulations [47]. U.M. Endelmann et al. used this method to calculate the heating efficiency of MNPs with a size of 10–30 nm and various values of effective anisotropy constant ($K = 4000$ J/m³– 11 J/m³) and damping parameter ($\alpha = 0.5\text{--}1$). The magnetic parameters of MNPs at the same time were obtained using VSM. Experimental and simulated results have shown that the maximum SLP value demonstrated particles in the 22–28 nm range. Moreover, MC simulation revealed a strong dependence of SLP on K [48]. Besides, various empirical and analytical methods are used to evaluate the SLP from an experimental setup, such as the initial slope, corrected slope, Box–Lucas, and steady-state methods [49]. Although recently developed bioheat models for MH are used to understand heat transfer phenomena in living tissue. These methods are fully considered in newly published articles by I. Raouf et al. [50] and M. Suleman et al. [51].

To optimize the experimental conditions, magnetic fluids of different compositions and volumes were analyzed in several laboratories. As a result, the necessary AMF parameters and sample volume were determined as $f = 300$ kHz; $H = 10.6 \text{ kA} \cdot \text{m}^{-1}$ – $15 \text{ kA} \cdot \text{m}^{-1}$, volume –1 mL [52].

For MH, the concentration, distribution, and retention of magnetic material within tumor volume are critical parameters. Currently, there are two main directions in MH dependent on the magnetic heating agent used and the manner of its intratumoral administration. Those are «Magnetic Fluid Hyperthermia» (MFH) [41–44,53,54] and «Arterial Embolization Hyperthermia» (AEH) [55–61]. These methods are based on the use of a liquid carrier medium typically containing magnetic iron oxide nanoparticles due to their good biocompatibility. The carrier medium is usually water or saline in MFH, while, in AEH, it is oily contrast media (Lipiodol Ultra Fluid, France, and its analogs) [56–63], and in-situ gelling materials [64] and low-viscosity polymers [65–69].

In clinical practice, the main problem of MFH is the way mediator administration which is realized either by direct intratumoral injection or intravenous medication that do not provide a uniform distribution of magnetic phase in the target tissue due to the typical heterogeneous structure of malignant tumors [54]. Therefore, heat distribution within tumors is not uniform, and there is a risk of proliferation of survived cancer cells. This method is also unacceptable for treating patients with hepatocellular carcinoma (HCC) due to the bleeding tendency in such highly vascularized tumors. Another problem of MFH is the low accumulation of particles in the cancerous area due to metabolism. Based on the clinical trials, the dose of magnetic phase for effective MFH is reported to be $40 \text{ mgFe/mL}_{\text{tissue}}$ per site, which is difficult to achieve in practice [31]. Indeed, as S. Wilhelm et al. reported, only 0.7% of nanoparticle dose can be delivered to a solid tumor [59]. However, despite these challenges, MFH has now received approval for clinical testing in humans by the German Federal Institute for Drugs and Medical Devices and the United States Food and Drug Administration to treat glioblastoma and prostate gland by colloidal suspension of aminosilane-coated iron oxide nanoparticles (NanoTherm[®], MagForce company, Berlin, Germany) [70–72]. This is most likely due to the development of a unique inductive heating applicator operating at an AMF frequency of 100 kHz with a field strength of up to 18 kA/m (MFH 300F NanoActivator[®]; MagForce Nanotechnologies AG, Berlin, Germany) [30].

In contrast to MFH, the challenges discussed above can be eliminated in AEH, developed to treat parenchymal organs. The concept of AEH is based on selective capacitive or inductive hyperthermia after transcatheter embolization of a tumor's arterial supply with a mixture of magnetic particles and an embolic agent [65–69]. As a result of embolization, the size of the tumor decreases due to a decrease in the blood supply, leading to partial necrosis of the tumor. The technique for transarterial embolization dictates the choice of materials for AEH. It depends on the patient's structural features and the treated lesion. However, the technique should meet the requirements of nontoxicity, nonantigenicity, stability to lysis, and radio-opacity. Moreover, at the delivery stage, the material should be of low viscosity to pass through angiographic catheters and fill up not only the main artery but also peripheral arteries and small blood vessels, i.e., ensure both proximal and distal embolization [66,67]. Then, the material should prevent blood flow, for example, due to the rapid increase of the material's viscosity.

The combined effect of embolization and hyperthermia on the tumor leads to ischemic necrosis of the tumor and programmed cell death, apoptosis. The first clinical trials of AEH were conducted 20 years ago at the Russian Research Centre for Radiology and Surgical Technologies (St. Petersburg, Russia) with the permission of the Russian Ministry of Health [67]. At the first stage of treatment, X-ray endovascular embolization with silicone composition containing microsized carbonyl iron particles (Ferrocomposite[®], Linorm, Saint Petersburg, Russia) was performed for 46 patients with stage III and IV renal cell carcinoma of the kidney [66]. The occlusion of the vascular system of the kidney was controlled angiographically. Then, 7–10 days after the post-embolization period, capacitive

RF hyperthermia was performed at a frequency of 27.12 MHz with an input power of 80 W. The temperature at the treatment area was monitored by an invasive method: needle-shaped temperature sensors were inserted into the peripheral parts of the kidney under ultrasound control. The treatment time of 30–45 min was necessary to heat a tumor to 43–45 °C. Morphological and histological analysis of kidneys after palliative nephrectomy showed the complete occlusion of the renal tumor blood supply and massive necrosis of the tumor tissue (Figure 2) [66]. As a result, 3–5-year survival of inoperable patients after embolization and hyperthermia was about 18% and 5%, respectively. Nevertheless, AEH based on the dielectric heating principle remains an experimental method in medical practice due to the difficulties associated with the overheating of healthy tissue. Contrariwise, the AEH method involving inductive heating principle (induction hyperthermia) has the advantage to heat selectively a tumor filled with ferromagnetic material without heat generation in the fat layers [68,69,73–75].




Figure 2. (a) Roentgenograph of the kidney after transarterial embolization with Ferrocomposite[®]; (b) Results of histological analysis indicating massive necrosis of tumor tissue of patient's kidney after ferromagnetic embolization and capacitive RF hyperthermia [66].

The purpose of this review is to demonstrate the potential of AEH for the treatment of deep-sited tumors of the vascular organs, kidneys, liver, and pancreas gland. Considering the strict limitations on the frequency and amplitude of AMF in MH, the heating ability of the mediator should be maximized considering the physical mechanisms responsible for the losses in magnetic materials. Therefore, the mechanisms of magnetic losses in nanomaterials are discussed to determine the relationship between the heating efficiency and magnetostructural properties of NPs. Besides, the role of interparticle magnetic interactions and the properties of the carrier medium on the heating efficiency are considered. The review also presents the results of *in vitro* and *in vivo* preclinical trials of magnetic nanomaterials in treating several oncological diseases using AEH.

2. Properties of Magnetic Materials for Their Application in Magnetic Hyperthermia: Nanomagnetism over Micromagnetism

The primary tenet of micromagnetism is that ferro and ferrimagnetic materials are mesoscopic continuous media where atomic-scale structure can be ignored since the magnetization (M), and the demagnetizing field (H_d) are nonuniform but continuously varying functions of distance (r) [76]. The main characteristic of macroscopic samples is the irreversible nonlinear response of M when exposed to an external magnetic field (H) (Figure 3).




Figure 3. Schematic representation of initial magnetization curve, hysteresis loop, and domain wall structure for a typical ferromagnetic material, where M_S is the saturation magnetization, M_r is the remanent magnetization at $H = 0$, and H_C is the coercivity.

In irreversible processes, energy is dissipated in the crystal lattice in the form of heat, known as hysteresis loss. The actual physical processes by which energy is dissipated during a quasistatic traversal of the hysteresis loop are identical to those responsible for the dynamic losses. In most materials with multidomain structures, the hysteresis of magnetization arises from domain wall motion or domain nucleation and growth.

There are several contributions to the free energy of magnetic samples with multidomain structure [77]:

Magnetostatic energy E_m , resulting from the interaction of atomic magnetic moments with local internal magnetic field H_i :

$$E_m = - \int_{\text{vol}} \mathbf{M} \cdot \mathbf{H}_i \, dV \quad (1)$$

Magnetic free energy, determined by an interaction between atomic magnetic moments and crystalline lattice expressed by magneto-crystalline energy E_k and magnetostrictive energy E_λ :

$$E_k = - \int_{\text{vol}} f_k \, dV \quad (2)$$

where f_k is magnetocrystalline anisotropy density

$$E_\lambda = - \int_{\text{vol}} f_\lambda \, dV \quad (3)$$

where f_λ is magnetostriction anisotropy density.

Free energy, which is related to the magnetic-exchange interaction.

The magnetostatic energy with dipole–dipole nature is inversely proportional to the volume of the particle, while the domain-wall energy is proportional to the area of the wall (Figure 4) [78]. Considering the balance between the magnetostatic energy and the domain-walls energy, the formation of a multidomain structure is energetically unfavorable when the particle size is less than the width of the domain walls.




Figure 4. The relative stability of multidomain and single-domain particles. Reprinted with permission [78]. Copyright 2021, Cambridge University Press.

Modern methods for studying the micromagnetic structure of materials, such as transmission microscopy and off-axis electron holography, as well as numerical micromagnetic simulation, revealed three typical magnetic configurations (states) in magnetic materials, depending on the particle size: single-domain (SD) with a uniform arrangement of magnetic moments, pseudo-single-domain (PSD) with a vortex spin arrangement, and multidomain (MD) structure where magnetic structure breaks up into discrete regions separated by domain walls (Figure 5) [79–82].




Figure 5. Schematic representation of the transitional state in magnets that spans the particle size range between SD and MD states. The inset collar pictures indicate the direction of the magnetic induction in magnetite particles with 25 nm, 200 nm, and microns sizes, modified from. Reprinted with permission [82]. Copyright 2021, American Chemical Society.

In the case of SD particles, these configurations may exhibit two states: (1) superparamagnetic (SPM) with unstable behavior due to the thermal instability of the magnetization if the thermal energy $k_B T$ ($k_B = 1.38 \times 10^{-23} \text{ J}\cdot\text{K}^{-1}$ is Boltzmann constant, and T is temperature sufficient to change the orientation of the magnetic moment of particle, and, (2) stable SD with ferromagnetic-like behavior when the magnetic moment is pinned along the magnetic anisotropy axis as a result of effective magnetic anisotropy [83].

For many practical applications, such as magnetic storage media and MH, the suitable particle size is within the range of a stable SD state, namely, in the vicinity of SD to PSD transition where the coercivity approaches maximum (Figure 5). The critical size for an SD magnetic state depends on several parameters, including M_S and K . For magnetite and maghemite approved for biomedical applications, the particle size range for the stable SD

state is about 20–80 nm for spherical particles and about 200 nm for elongated particles with 2:1 axial ratio [83,84].

The magnetization reversal mechanism in nanosized magnetic materials differs from that for MD ferromagnets. In SD particles smaller than 100 nm, magnetization occurs only by coherent rotation of all atomic magnetic moments within the sample against an energy barrier (ΔE) given mainly by the shape and the crystalline anisotropy fields [85–90]:

$$\Delta E = K - HM_S |\sin \varphi| \pm HM_S \cos \varphi \quad (4)$$

where K is the anisotropy energy density, and φ is the angle between the easy axis and the magnetic field.

The shape anisotropy comes from the demagnetizing field:

$$H_d = -N_d M_S \quad (5)$$

where N_d is the demagnetizing shape factor of a magnetized unit.

A dominant effect of the size and shape anisotropy on H_C and M_S and the heating efficiency has been observed in anisotropic magnetite NPs, such as wire, ring, rod, cube, octahedron, etc. (Figure 6) [87–90].




Figure 6. (a) SAR vs. H for the Fe_3O_4 NPs (spheres, cubes, nanorods) with the volume of about 2000 nm^3 , (b) SAR vs. H for the sphere and cube-shaped Fe_3O_4 NPs dispersed in water under AMF (300 kHz, from tens to 800 Oe). Reprinted with permission [87,88]. Copyright 2021, American Chemical Society.

It is known that MNPs with particle sizes larger than 20 nm are in a stable-domain state with ferromagnetic-like behavior when the magnetic moment is pinned along the magnetic anisotropy axis as a result of effective magnetic anisotropy. Such NPs exhibit much higher heat loss in AMF. This class of magnetic nanomaterials also includes the novel octahedral monocrystalline magnetite NPs obtained by thermal decomposition [91]. Owing to the octahedral morphology, these NPs show one of the largest SARs rates reported to date for a colloidal suspension of magnetite: $1000 \text{ W/gFe}_3\text{O}_4$ at 40 mT and 300 kHz. Such behavior has been explained by the shape of NPs that imprints a biaxial or bi-stable character to the magnetic anisotropy.

Besides the size and shape, other properties of magnetic NPs should be considered for modulating the heat generation, such as particle size distribution and the presence of interparticle interactions.

The polydisperse sample represents an ensemble (mixture) of particles with various magnetization states corresponding to the distributions in magnetic properties, especially the magnetic anisotropy, which governs the height of the energy barrier. Many works have been focused on how polydispersity influences the hyperthermia performance of magnetic NPs. The detrimental influence of size polydispersity (σ) on the heat outcome is usually reported as follows: heat generation can drop between 30% to 50% for σ varying between 0.2 and 0.4 [92–94]. However, the decrease in the heating efficiency in polydisperse materials can be associated not only with polydispersity per se but also with low (unsaturated) magnetic field strength [95]. The use of low amplitudes in the experiments results from a number of unsuccessful attempts in clinical trials to apply the amplitudes of AMF beyond 15 kA/m. For example, M. Johannsen et al. reported that patients undergoing thermotherapy treatment of prostate cancer with exposure to AMF of 100 kHz felt discomfort at amplitudes higher than 5 kA/m [30], whereas for the treatment of brain tumor, field strength up to 13.5 kA/m was reported to be well tolerated [71]. Therefore, in each treatment case, the frequency and amplitude of AMF must be correctly selected regardless of the polydispersity of particles.

As mentioned above, along with polydispersity, the interparticle interactions can significantly affect the magnetization dynamics of NPs, since they lead to aggregation, especially when particles are without surface coating.

In an ensemble of noninteracting SD NPs, the energy losses are associated with the Neel–Brown relaxation process [95]:

$$\tau_N = \tau_0 \exp \left\{ \frac{KV_C}{k_B T} \left(1 - \frac{H}{H_A} \right)^2 \right\}; \quad \tau_B = \frac{3V_h \eta}{k_B T} \quad (6)$$

where τ_N and τ_B are time scales of Neel and Brownian relaxation, τ_0 is a pre-exponential factor ($10^{-9} \div 10^{-11}$ s), H_A is the anisotropy field equal to $2 K/\mu_0 M_S$, V is the particle volume, η is the viscosity of the carrier medium, V_h is the hydrodynamic volume of the particle, and H is the field amplitude.

For a material in which both Neel and Brown relaxation takes place with an effective relaxation time τ_{eff} , the mechanism with shortest τ_{eff} dominates. However, due to the exponential dependence of τ_N on the particle volume, while τ_B linearly grows with hydrodynamic volume, different Neel and Brownian contributions can be realized for the same magnetic material with different particle sizes (Figure 7a) [95,96]. Both relaxation processes strongly depend on the amplitude of AMF. It is established that the Neel mechanism manifests itself predominantly at high field amplitudes, while at low field amplitudes, the Brownian mechanism prevails [97]. In addition, the relaxation time of a Brownian process is proportional to the viscosity of the carrier medium; thus, Brownian relaxation is largely suppressed when the particles are immobilized in a viscous medium such as cancerous tissue (Figure 7b) [98].




Figure 7. (a) Néel and Brown relaxation times calculated over a range of particle sizes for a water-based magnetite ferrofluid [96]; (b) Imaginary part of susceptibility of maghemite based aqueous suspension in comparison to the identical particles immobilized in the gel. Reprinted with permission [96,98]. Copyright 2021, Elsevier.

The assembly process of magnetic NPs in liquid media is driven by the attractive–repulsive interactions between NPs, van der Waals (vdW), magnetic, electrostatic, and solvophobic forces [98–100]. The former two are core–core interactions that dominate the interaction potential and hold NPs together. The van der Waals interactions scale linearly with the particle’s radius, while the magnetic interaction scales with its volume. Magnetic interactions always coexist with vdW forces, which becomes increasingly important with decreasing particle size. For example, the formation of aggregates from NPs in the absence of an external magnetic field already takes place at the beginning of coprecipitation reaction; thus, the contribution of vdW forces can be notable (Figure 8) [93]. However, the formation of dense aggregates that are stable against segregation into individual nanoparticles is possible only under the influence of interparticle magnetic interactions [100]. Estimating the threshold sizes for the agglomeration of magnetite NPs has shown that they are relatively stable against agglomeration up to 20–25 nm in diameter [101,102].




Figure 8. (a) TEM image of the five-minute reaction product for magnetite synthesized by coprecipitation method, and (b) particle size distribution histogram. Reprinted with permission [93]. Copyright 2021, American Chemical Society.

The interactions between magnetic NPs are interpreted in terms of magnetodipole and exchange interactions. Exchange interaction can be neglected when interparticle spacing is of the order of 2 nm, which approximately corresponds to the distance between two NPs with a dead layer of thickness of about 1 nm [93]. In most cases, the dominant contribution to interparticle energy is a magnetodipole coupling, which increases with the volume of NPs and depends on the mutual distance between particles [103–105].

Dipole–dipole interactions can be either attractive (in-line dipoles) or repulsive (antiparallel aligned dipoles). The predominant type of configuration of dipoles is the antiparallel orientation of the magnetic moments of a pair of particles [93,106]. Subsequently, the pair of dipoles stick together to form larger aggregates, and, in the absence of an external field, these aggregates have closed magnetic flux with random orientation of magnetic moments of individual NPs (Figure 9).




Figure 9. (a) Schematic picture of dense aggregate (multicore particle) with surface coating [106], (b) TEM image of magnetite NPs clustered into dense aggregate, and (c) particle size distribution in aggregate. Reprinted with permission [93,106]. Copyright 2021, Elsevier, and American Chemical Society.

Even though NPs in the aggregate are in the SPM state, in some cases, the material itself may demonstrate ferromagnetic-like behavior, which is evidenced by distinct sextets on the Mössbauer spectrum and blocking temperature well above room temperature on the FC/ZFC curves (Figure 10) [107].




Figure 10. (a) Mössbauer spectroscopy and (b) FC/ZFC magnetization curves of as-prepared magnetite NPs in a powder form. Reprinted with permission [107], Copyright 2021, Elsevier.

The ferromagnetic-like behavior of such materials can be explained by the internal structure of the aggregate formed, namely, when SPM NPs are combined into a dense 3D cluster, the so-called multicore particles [105,107,108] and nanoflowers [109]. These materials can provide efficient and rapid heating in AMF at low-field regimes [110].

The experimental results and numerical simulations have shown the different effects of inter and intra-aggregate magnetodipole interactions on heat generation [93,107–113]. It is found that an increase in the concentration of NPs leads to a nonmonotonic behavior of SAR (SLP) with its reduction at a specific aggregate size (Figure 11).




Figure 11. (a) SLP for water and agar dispersions of magnetite-based multicore particles as a function of hydrodynamic size in AMF of 1048 kHz and 5.8 kA/m [93]; (b) Effect of intra and intercluster magnet–dipole interactions in the dispersion of magnetite NPs on SAR as a function of concentration and hydrodynamic cluster size (D_H) obtained under the given AMF conditions of 105 kHz and 13.1 kA/m [111]. Reprinted with permission [93,111]. Copyright 2021, Elsevier and Royal Society of Chemistry.

A theoretical study of the effect of magnetodipole interactions on the heating ability of an ensemble of particles, and especially multicore particles, is challenging since it is a multiparameter task that must account for the magnetic characteristics of primary particles, as well as morphostructural properties, i.e., polydispersity, shape anisotropy, packing density of NPs in a cluster, etc. [114–117].

An increase in the heating ability is usually explained either by a change in the characteristic height of the energy barrier related to the thermal energy [92] or by a change in the magnetic state due to the collective behavior of closely spaced NPs [84,85,113,114]. In turn, a decrease in the heating ability in the ensemble of interacting NPs is explained by the disorienting effect of a random magnetic field, causing a deviation of the magnetic moments of NPs from the direction of the AMF [116].

The nanoparticle size is one of the most important parameters that affects the magnetic properties of multicores. The study of the heating ability of multicore particles of approximately the same hydrodynamic diameter (100 nm) but formed by magnetite NPs of different sizes (7.1 and 11.5 nm) showed different results [118]. Both types of multicores improve their heating efficiency compared with individual NPs when exposure to AMF at $f = 302$ kHz and $H = 15$ kA/m, but multicores composed of larger NPs show two times higher values of SAR. The crucial role of core particle size in a cluster has also been established by C.H. Jonasson et al. They investigated the heating efficiency for SD particles of different sizes and multicore particles both experimentally and theoretically using dynamic Monte-Carlo simulations [119]. It was found that for a given AMF (1 MHz, 3–10 kA/m), core–core interactions can lead to a different character of ILP dependence on the core diameter (D_c) when D_c is higher or lower than the size maximizing the ILP value, i.e., $D_c = 20$ nm (Figure 12).

Apart from magnetite and maghemite single phase-based systems, exchange-coupled magnetic NPs have been proposed so far as possible candidates for efficient MH. These particles have a core–shell structure with different combinations of magnetically soft and hard materials, for example, $\text{CoFe}_2\text{O}_4@Mn\text{Fe}_2\text{O}_4$, $\text{CoFe}_2\text{O}_4@Fe_3\text{O}_4$, $Fe_3\text{O}_4@CoFe_2\text{O}_4$, $\text{CoFe}_2\text{O}_4@γ\text{Fe}_2\text{O}_3$, $FeO@Fe_3\text{O}_4$, etc. [120–123]. The main idea underlying exchange-coupled magnetic NPs in MH is to increase the hysteresis losses by controlling the anisotropy constant (K) while maintaining superparamagnetism, thereby preventing aggregation and the formation of large clusters. The magnetic properties of exchange-coupled core–shell particles and their effect on SLP are dependent on the composition, as well as on the core and shell size (Figure 13). As can be seen from this figure, the SLP of core–shell NPs exhibits

SLP values significantly higher than the SLP of single-phase magnetic NPs; however, the amplitude of AMF is twice the value allowed for medical application.




Figure 12. (a) Experimental (red) and simulated ILP data analysis for noninteracting (blue) and interacting single-core particles (green); (b) Simulated ILP versus the number of cores in a core cluster for two core sizes, below (6 nm) and above (28 nm) the core size maximizing the ILP value. Reprinted with permission [119]. Copyright 2021, Elsevier.




Figure 13. (a) Schematic representation of an exchange-coupled core–shell CoFe₂O₄@MnFe₂O₄ nanoparticle and its SLP value compared with SLP values of single-phase CoFe₂O₄ and MnFe₂O₄; (b,c) SLP values of various combinations of core–shell NPs and single-component NPs measured at $f = 500$ kHz and $H = 37.3$ kA/m. Reprinted with permission [120]. Copyright 2021, Springer Nature.

To sum up, dynamic magnetic properties and an increase in the heating efficiency of the mediator (for given amplitudes and frequencies of AMF) are determined by the following factors: (1) material composition and degree of crystallinity; (2) average particle size within the range of stable SD state, which is between 16–20 nm in diameter for ferrimagnetic iron oxides; (3) particle size distribution (preference to monodispersity over polydispersity), and (4) magnetodipole interaction. The first affects K and M_S , the next two control the interaction strength of NPs, thus regulating the hydrodynamic size and internal structure of multicore particles, and the last one determines collective magnetic behavior and thus modifies the amount of heat generation during the hyperthermia session.

3. Magnetic Materials for Application in AEH

As already mentioned in the introduction, AEH is a multiple treatment modality involving transarterial embolization of tumors with magnetic material followed by exposure to AMF at clinically relevant frequencies and amplitudes. The embolotherapy itself is widely used in clinical practice for diagnostic (coronary angiography), preoperative management of malignant renal tumors, chemoembolization of malignant hypervascular tumors such as hepatocellular carcinoma, as well as in the treatment of aneurysms, hemorrhage, angiomyolipoma, and other conditions [63,67,124].

At the first stage of the treatment by AEH, transcatheter injection of the embolic agent is administered under an angiographic control. This procedure usually lasts about 20–25 min. During this time, the embolic agent should maintain low viscosity ($\eta < 0.5$ Pa/s) for transportation and filling of the tumor vascular system. After this induction period, the viscosity should increase rapidly with forming a soft and stable embolus, which can occlude the tumor blood vessels. The selective MH can be carried out after the passing of the post-embolization period of patients (fever, elevated white blood count, etc.), which usually takes from one to two weeks [66,67].

Embolic agents are generally classified into mechanical [56] and flow-directed agents, but only the latter is used in AEH as a carrier of magnetic particles. The list of such materials includes Lipiodol (Lipiodol Ultra Fluid, Guerbet, France) and its analogs [57,60,63,125], in-situ gelling materials (e.g., Onyx[®] (DMSO, Acros Organics, Basel, Switzerland): ethylene-vinyl alcohol copolymer dissolved in dimethylsulfoxide, etc.) [64,126], and low-viscosity polymers (polyorganosiloxanes, radiopaque degradable polyurethane) [65–69,127–129].

Most studies on the effectiveness of AEH have been conducted in vivo in mouse and rabbit models with liver cancer disease after hepatic intra-arterial injection of magnetic NPs suspended in Lipiodol [59–63,130–133]. The use of Lipiodol as a carrier medium is determined by a set of its properties: radio-opacity (~48% of iodine), ability to induce plastic and transient embolization of tumor, microcirculations causing ischemic necrosis of tumor, limiting the ingress of viable cancer cells as well as their debris in the bloodstream. With the right choice of the magnetic particle size and concentration in Lipiodol, it is possible to achieve a homogeneous intratumoral distribution of the magnetic phase and, thus, to significantly increase the specific heating of the tumor, but only at field amplitudes of about 20 kA/m and higher, which is beyond the permissible limit in MH (Figure 14) [62].




Figure 14. (a) Temperature change at the tumors of mice with hepatocellular carcinoma after injection of magnetite NPs emulsion in Lipiodol (cBNf-lip) followed by MH at 155 kHz and amplitudes within 14–28 kA/m. (b) TEM image of cBNf-lip. Reprinted with permission [62]. Copyright 2021, Taylor & Francis.

Similar results were obtained earlier by Moroz et al., who reported the superiority of AEH compared with direct injection hyperthermia, studied on a model of a rabbit liver tumor [58,60,133]. It was found that after hepatic arterial embolization by maghemite NPs (100–200 nm) suspended in Lipiodol and subsequent MH (53 kHz, 30–45 kA/m), the tumor

volume can be reduced by almost 94%, depending on the particle concentration and the uniformity of its distribution in the tumor.

Along with Lipiodol, other materials have been investigated as embolic agents in AEH. Exemplarily, the embolic properties and heating efficiency of organogel (Onyx[®]) containing silica microbeads filled with magnetic iron oxide NPs have been studied in nude mice carrying subcutaneous human carcinomas [64,126]. Thus, the intratumoral injection of nanocomposite followed by 20 min MH at 141 kHz resulted in extensive tumor necrosis (78%) but only for a group of animals exposed to AMF of high intensity (~12 mT) (Figure 15). At such an intensity of AMF, the tumor heats up to 44–45 °C, thus, undergoing thermal ablation. A survival study using magnetic resonance imaging has shown that 45% of the 12 mT-treated groups survived one year without any tumor recurrence.




Figure 15. Thermogram of mean intratumoral tumor temperature as a function of treatment time and magnetic field strength. Reprinted with permission [64]. Copyright 2021, Taylor & Francis.

Despite the demonstrated efficacy of AEH *in vivo*, some obstacles remain that limit the use of this method in clinical practice, namely, difficulty in assessing the actual temperature of tumors. It is generally clear that, for successful performance of AEH, two significant factors should be accomplished simultaneously: achieving the total embolization of the tumor vascular system and attaining hyperthermia temperatures causing ischemic necrosis of the tumor. Thus, a balance must be achieved between the mechanical properties of embolic agents comprising low initial viscosity, rapid solidification, and robust embolus stiffness. From that perspective, the biocompatible polyorganosiloxanes are promising embolic agents: (1) their viscosity and the curing rate can be regulated by their composition, (2) silicone elastomers do not display adhesion to living tissues, (3) they are soft materials and do not injure blood vessels [134]. Moreover, silicones closely adjoin the walls of blood vessels, reducing the probability of blood flow recovery. The low specific heat of silicon rubber of 1.05–1.30 J/g·K is also advantageous because it favors the distribution of the heat generated by incorporated magnetic particles [73]. The advantage of using these polymers for transcatheter embolization in patients with renal cell carcinoma was demonstrated with Ferrocomposite[®] (Saint Petersburg, Linorm, Russia) [65–69]. The X-ray image (Figure 2a) shows a patient's kidney with a large tumor uniformly filled with Ferrocomposite[®]. Complete occlusion of renal tumor blood supply results in necrosis of tumor tissue, and in combination with RF capacitive hyperthermia, it provided in massive necrosis (Figure 2b). Considering the positive results of clinical trials of Ferrocomposite[®], further research aimed to improve its properties: reducing the viscosity of the embolic agent and increasing its heating ability in AMF permitted for medical application. As a result, maghemite-based silicone composition (Nanoembosil[®]) (Saint Petersburg, Linorm, Russia) was developed, which possesses a set of properties required for its use as a mediator in AEH: the ability for secure embolization of the tumor blood vessels, the high heating rate in AMF at moderate frequencies, and amplitudes, and radiopacity [68,69]. Nanoembosil[®]

has been tested in vitro at the Tomas Bata University in Zlin (CZ) and in vivo at Moscow's Blokhin Russian Cancer Research Centre.

4. Nanoembosil[®]: Synthesis, Characterization, In Vitro and In Vivo Study

The magnetic phase of Nanoembosil[®] is maghemite NPs prepared by annealing (6 h at 300 °C) of magnetite NPs synthesized by coprecipitation method under certain reaction conditions that guarantee the formation of monodisperse NPs with a high degree of crystallinity [107,135]. The annealing does not change the morphology of NPs but predictably decreases the M_S value. Notably, the original (as-prepared) and annealed samples demonstrate almost identical heating efficiency (Figure 16), which can be explained by increased effective anisotropy due to magnetodipole interactions resulting in the formation of stable multicore particles (Figures 8 and 9).




Figure 16. Inductive heating of magnetite (a) and maghemite (b) glycerol dispersions in AMF (525 kHz, 7.6 kA/m). Reprinted with permission [107]. Copyright 2021, Elsevier.

The characteristics of raw materials used for the preparation of Nanoembosil[®] are presented in Tables 1 and 2.

Table 1. Magnetic phase: Iron oxide NPs Structural and magnetic properties.

Property	Magnetite	Maghemite
d_{TEM} (nm)	13	13
σ_{TEM}	0.3	0.3
d_{XRD} (nm)	12	12
ε (%)	0.3	0.6
Magnetite content determined from XRD (%)	72	8
Magnetite content determined from MS (%)	60	0
M_S (emu g^{-1})	56 ± 2	48 ± 1
M_r (emu g^{-1})	0.8 ± 0.2	0.8 ± 0.2
H_c (Oe)	11 ± 4	10 ± 3
SLP (W/g_{Fe})	23.0 ± 0.6	20.3 ± 1.5

d_{TEM} , d_{XRD} —average particle size determined by TEM and XRD, respectively; σ_{TEM} —polydispersity index; ε —crystal lattice strain; M_S —Mössbauer spectra.

Table 2. Polymer phase: Characteristics of raw polymer for Nanoembosil[®] preparation.

Reagent	Molar Weight (g·mol ⁻¹)	Polydispersity	Viscosity @ 25 °C (Pa·s)	Concentration of Substitutions (wt. %)
PVS	100,126	1.62	2.6	0.1–0.4, vinyl groups
PHS	17,202	1.83	0.65	0.55, hydrosstitutions
PDMS	73,78	1.20	0.03	-
CTS	345	-	3.9	-
Speier's catalyst	-	-	-	Hexachloroplatinic acid [H ₂ PtCl ₂].H ₂ O dissolved in PDMS
Karstedt's catalyst	-	-	-	Platinum [0] complex containing vinyl–siloxane ligands


PVS [poly(dimethylsiloxane-co-methylvinylsiloxane)]; PHS [poly(dimethylsiloxane-co-methylhydrosiloxane)]; PDMS [poly(dimethylsiloxane)]; CTS/Cyclotetrasiloxan [1,3,5,7-tetravinyl-1,3,5,7-tetramethylcyclotetrasiloxane].

The Nanoembosil[®] is supplied in two compositions in separate containers: the first contains PVS, catalyst, maghemite NPs, and radiopaque potassium iodide (KI) (Container 1), whereas the second contains PHS, CTS, and PDMS (Container 2). Once the content of Container 2 is added into Container 1, the hydrosilylation reaction of hydro- and vinyl-functional silicone polymers starts. To monitor the polymerization process, the optimal concentration of reagents was chosen to provide low initial viscosity (0.25–0.3 Pa/s) during the induction period (20–25 min), followed by an abrupt increase in viscosity and the formation of a soft embolus (Table 3). To this end, the impact of each component on the kinetics of Nanoembosil[®] formation was investigated through measurements of the rheological properties on a Rheometer with parallel plate geometry. Variation of rheological properties of the composite during its formation is presented in Figure 17.

Table 3. Nanoembosil[®] composition.

Composite Type	Concentration of the Initial Components, wt. %							η^*_{in}	η^*_{fin}	t_{in}
	PVS	CAT	PHS	PDMS	CTS	NPs	KI			
I	40	2	11	33	-	7	7	0.3	3000	20
II	36	2	10	32	6	7	7	0.25	3000	25

η^*_{in} is initial viscosity, η^*_{fin} is final viscosity, t_{in} is the duration of the induction period.

**Figure 17.** Kinetics of Nanoembosil[®] formation. Reprinted with permission [68]. Copyright 2021, Elsevier.

As it can be seen from this figure, no changes in the elastic modulus (G') and viscous modulus (G'') of complex shear modulus G^* are observed at the beginning of the reaction,

and the system's viscosity stays constant, which corresponds to the induction period of the reaction. The complex shear modulus is defined as [136]:

$$G^* = \frac{\tau^*}{\gamma_M} = \sqrt{G'^2 + G''^2}, \quad (7)$$

where τ^* is the complex stress, and γ_M is the maximum value of fixed strain.

During the induction period, the composition is fluid, evidenced by a greater value of G'' over G' . As the reaction between vinyl- and hydro-groups starts, both G' and G'' increase, but G' increases faster than G'' . At the end of the induction period (~20 min), there is an intersection between G' and G'' , indicating reaching the vulcanization point. Above the vulcanization point, the elastic component dominates over the viscous one, $G' > G''$; the viscosity of the composition rapidly increases till it reaches a maximum and then stays constant after all the hydro-groups have reacted. Thus, the dominant influence on the kinetics of composite formation is exerted by PHS, PVS, PDMS, and CTS, where the last two components play the role of plasticizers to adjust composite viscosity. As to the influence of the magnetic filler concentration on the rheological properties of the composite, it is negligible up to 14 wt.%.

The heating efficiency of Nanoembosil[®] was estimated in the AMFs at frequencies and amplitudes ($f = 0.05\text{--}1.5$ MHz, $H \leq 15$ kA·m⁻¹) standardized for medicine. The heating rate of the composites, as well as SLP, depends on the AMF parameters since the magnetization process is determined solely by the Neel relaxation (Figure 18, Table 4). Nevertheless, according to the results obtained, a high heating rate can be achieved in the entire frequency range even at sufficiently low field amplitudes. Therefore, an increase in SLP in composites of this type is possible with increased field amplitude to the allowed power level.




Figure 18. Inductive heating of composites with 7 wt.% of NPs at different alternating magnetic field parameters. Reprinted with permission [68]. Copyright 2021, Elsevier.

Table 4. SLP values ($W \cdot g_{Fe}^{-1}$) and heating rates ($^{\circ}C/min$) of Nanoembosil[®] in AMF of various frequencies and amplitudes.

AC Magnetic Field	f (kHz)	114	525	1048	
	H (kA·m ⁻¹)	13.8	5.8	7.6	5.8
SLP		8.6 ± 0.1	4.3 ± 0.4	8.6 ± 1.0	9.0 ± 1.5
Heating rate	($^{\circ}C \cdot min^{-1}$)	13.8	5.8	7.6	5.8

Considering that the embolic agent should also possess thermal expansion similar to or higher than blood to prevent the blood flow recovery during hyperthermia session,

the thermomechanical properties of Nanoembosil[®] were studied by dynamic mechanical analysis. The study revealed that the material possesses the rubber-elastic properties: shear modulus, G' , is almost independent of the applied frequency, and the loss tangent, $\tan \delta$, is slight (0.1–0.2) (Figure 19). The value of G' within the range of hyperthermia temperatures slightly increases from 9.6 to 9.9 kPa at 38 °C and 10 Hz shear rate. The obtained shear modulus values are smaller than those reported for the artery, 30–3000 kPa [136,137]; thus, the composite will easily deform with the artery. Furthermore, the thermal expansion coefficient of the composite is 760 ppm °C⁻¹ at 37 °C and slightly decreases to 710 ppm °C⁻¹ with the temperature rise to 45 °C. The high value of α for the composite ensures the prevention of blood flow recovery during heating.




Figure 19. Temperature dependence of shear modulus and loss tangent at different shear rates for Nanoembosil[®]. Reprinted with permission [68]. Copyright 2021, Elsevier.

In vivo study of Nanoembosil[®] was done at the N.N. Blokhin Russian Cancer Research Centre in Moscow. The study aimed to determine the embolic agent dose for intra-arterial administration and filling the tumor vascular system and estimate its antitumor effect [138]. All experiments were conducted according to the National and European guidelines on the ethical use of animals [139,140]. Throughout the procedures, animals were anesthetized with Zoletil 100 (Virbac, Carros, France). The experimental study was performed using 25 rats (8-week-old males of body weight 200 g) and 16 male rabbits weighing 2.0–3.0 kg. Some animals were kept healthy to estimate tolerability of embolization, and others were intramuscularly implanted with hepatocellular carcinoma PC-1 (rats) and VX2 (rabbits). It was established that intravenous tissue tolerance of embolic agents for rats is 0.1 mL for the composition I with $\eta_{in}^* = 0.3$ Pa/s, and 0.2 mL for composition II with $\eta_{in}^* = 0.25$ Pa/s, while for rabbits, 1.5 mL, which is well below the guidelines for the maximum intravenous injection volumes of experimental compounds in rats and rabbits [141]. Thus, the study of the effect of embolization on tumor growth was conducted using the established volumes of compositions. To this end, four independent animal groups with the same number of rats ($n = 5$) were used. Animals in group 1 were exposed to embolization by composition I (0.1 mL) and in groups 2 and 3, respectively, by composition II with volumes of 0.1 mL and 0.2 mL. To monitor the treatment of tumor growth, the test group received only a physiological solution.

The embolization was carried out on the 20th day after transplantation when a full regional blood flow in the tumor node was formed. The embolic agents were prepared extempore and administered once by transarterial infusion into the femoral artery using an intravenous catheter.

The efficacy of embolization was estimated according to standard criteria: inhibition of tumor growth, tumor growth dynamic (3, 7, 10, and 14 days after embolization), tumor doubling time (τ_2), and therapeutic response ($\tau_{trial}/\tau_{control}$). The tumor growth was estimated by the change in the tumor volume (V_t/V_0), where V_0 is the mean volume of

the tumor before, and V_t is the mean volume of the tumor after treatment. The results of in vivo study are presented in Table 5 and Figure 20.

Table 5. The effect of embolization by silicone-based magnetic composites on the dynamics of PC1 tumor growth in rats.

Group of Animals	Dose (mL)	V_t/V_0		τ_2 (Days)	$\tau_{\text{trial}}/\tau_{\text{control}}$ (%)
		n Days after Embolization			
		3	7		
Test group saline infusion	0.2	2.3	5.3	3.0	-
Group 1 Composite I	0.1	1.4	2.5	6.0	2.0
Group 2 Composite II	0.1	1.4	2.5	6.0	2.0
Group 3 Composite II	0.2	1.2	1.5	>11	4.0




Figure 20. Inhibition of rat liver tumor growth after embolization of tumor vascular system by silicone-based magnetic composites: 1: test group; 2: embolization with composite I (administrative dose 0.1 mL); 3: embolization with composite II (administrative dose 0.2 mL); standard deviation is ± 0.5 .

Accordingly, in the case of the test group of rats, the tumor growth rate increased by a factor of 1/5. The embolization of the tumor vascular system by both types of compositions significantly inhibits the tumor growth, and this effect is more pronounced in the case of embolization by Nanoembosil[®] (composition II). Indeed, over a period of seven days after embolization, the rate of tumor growth was two times lower in group 3 compared with the test group. This is due to the low viscosity of composition II (0.25 Pa/s), which allowed one to increase the administered dose without causing side effects.

Similar results were obtained in rabbits with intramuscularly transplanted VX-2 liver cancer. Intra-arterial injection of Nanoembosil[®] at a dose of 1.5 mL on the 20th day of tumor growth led to a significant decrease in growth rate within two weeks. Stabilization of tumor growth within 14 days is associated with tumor cytoreduction by more than 50%.

The efficacy of silicone-based magnetic composites as heat mediators was studied in vitro on the human Hepatocellular carcinoma cell line (HepG2). The treatment was conducted in the following scheme. Prior to in vitro testing, a certain amount of Nanoembosil[®] was mixed with cells in the ratios of 1:1 and 2:1, which correspond to iron concentrations of 3.5 and 5 g/L in the tested value. All samples were preheated to 37 °C in a hot water bath and further heated up to 44 °C via a homemade inductive heating applicator (Figure 21).




Figure 21. Laboratory device for measuring the heating ability of materials and conducting in vitro and in vivo studies: (a) signal generator, (b) signal amplifier, (c) AMF amplitude meter, (d) temperature recorder with fiber optic thermocouples, (e) sample holder, (f) schematic illustration of a device with a horizontal position of an impedance coil for in vivo study.

The measurements were carried out in AMFs with frequency 525 kHz and amplitude of about $9 \text{ kA} \cdot \text{m}^{-1}$. After reaching $44 \text{ }^\circ\text{C}$, this temperature was maintained for 30 min, which is a common treatment time for hyperthermia sessions [5]. To determine cell viability, the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium) test was performed. The results obtained indicate the cytotoxic effect of the hyperthermia treatment with Nanoembosil[®]. Moreover, the observed effect increases with the concentration of the mediator (Figure 22).




Figure 22. Results of in vitro test for magnetic hyperthermia-treated HepG2 cells. The AFM parameters are $f = 525 \text{ kHz}$, $H = 9 \text{ kA} \cdot \text{m}$.

5. Concluding Remarks and Future Perspectives

Of considerable interest is the development of magnetic polymeric composites to treat malignant tumors of parenchymal organs by AEH. In this method, it is possible to achieve significant benefits from the dual effect of embolization of the tumor vascular system and subsequent MH. Embolization blocks the tumor due to the stagnation of its blood supply and leads to the shrinkage of the tumor. In turn, magnetic hyperthermia promotes the heating of the tumor to temperatures of $43\text{--}44 \text{ }^\circ\text{C}$ and can be repeated several times. The combined effect of embolization and hyperthermia on a tumor leads not only to ischemic necrosis but also to programmed cell death (apoptosis). Moreover, AEH combined with RT and ChT can significantly improve the survival of patients with various types of cancer.

The clinical purposes dictate the choice of materials for AEH. Thus the development of silicone-based magnetic composites that possess the set of properties necessary for conducting AEH, namely, the ability for secure embolization of the tumor blood vessels, radiopacity, and the high heating rate at moderate frequencies and amplitudes of AMFs, allowed for medical applications. The possibility of securing embolization was achieved by the optimization of the composition of the embolic agent to provide low initial viscosity ($0.2\text{--}0.3\text{ Pa}\cdot\text{s}^{-1}$), allowing the delivery and distribution of the material uniformly in tumor's blood vessels, and 20–25 min induction period after which the viscosity of the composite rapidly increases forming soft embolus. Such embolus displays rubber-elastic properties with shear modulus lower than arteries, within the range of HT temperatures, and higher thermal expansion coefficient than blood. Therefore, silicone-based magnetic elastomer can deform with the blood vessels and prevent blood flow recovery during heating.

The in vivo study has shown that intra-arterial administration of Nanoembosil[®] to animals with intramuscular developed tumors (PCI/mouse and VX2/rabbits) significantly inhibits the tumor growth rate. In vivo study of Nanoembosil[®] should be continued towards using a combined method including embolization followed by MH. Moreover, when studying the dynamics of tumor growth, the possible influence of colloidal platinum, which is formed during the hydrosilylation reaction of hydro- and vinyl-functional silicone polymers, must be considered. In vitro and in vivo study have shown that Pt-NPs can lead to high toxicity due to their large surface area [142].

To increase the effectiveness of the MH, in addition to mastering the shape and size of magnetite and maghemite NPs, other ferro- and ferri-magnetic materials can be used to increase the heating efficiency in AMFs at moderate frequencies and amplitudes, such as exchange-coupled MNPs with a core-shell structure [120], as well as hybrid systems, that is, combinations of soft and hard magnets or iron oxide NPs doped with Co [143]. The transarterial embolization must be controlled by enhancing the X-ray contrast with the addition of radiopaque materials or binding radionuclides to coated MNPs [144].

The future challenge lies in developing mathematical heat transfer models in tumors and their surrounding biological tissue to preserve healthy tissue [145].

Author Contributions: All authors have made a substantial and direct intellectual contribution to this article. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Ministry of Education, Youth and Sports of the Czech Republic–DKRVO (RP/CPC/2020/005), Program Multilateral Scientific and Technological Cooperation in the Danube Region (8X20041).

Acknowledgments: The research of the development of magnetic polymeric materials for AEH was carried out under the direct guidance and with the active participation of Kira N. Makovetskaya. The research resulted in the development of ideas about the magnetic polymeric materials usage in locoregional methods applied for cancer patients' treatment. We, her colleagues, dedicate this work to the blessed memory of our teacher.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J. Clin.* **2021**, *71*, 209–249. [[CrossRef](#)]
2. Myerson, R.J.; Moros, E.G.; Diederich, C.J.; Haemmerich, D.; Hurwitz, M.D.; Hsu, I.J.; McGough, R.J.; Nau, W.H.; Straube, W.L.; Turner, P.F.; et al. Components of a hyperthermia clinic: Recommendations for staffing, equipment, and treatment monitoring. *Int. J. Hyperth.* **2014**, *30*, 1–5. [[CrossRef](#)]
3. Datta, N.R.; Ordonez, S.G.; Gaip, U.S.; Paulides, M.M.; Crezee, H.; Gellermann, J.; Marder, D.; Puric, E.; Bodis, S. Local hyperthermia combined with radiotherapy and-/or chemotherapy: Recent advances and promises for the future. *Cancer Treat. Rev.* **2015**, *41*, 742–753. [[CrossRef](#)]
4. Kroesen, M.; Mulder, H.T.; van Holthe, J.M.L.; Aangeenbrug, A.A.; Mens, J.W.M.; van Doorn, H.C.; Paulides, M.M.; Oomen-de Hoop, E.; Vernhout, R.M.; Lutgens, L.C.; et al. Confirmation of thermal dose as a predictor of local control in cervical carcinoma patients treated with state-of-the-art radiation therapy and hyperthermia. *Radiother. Oncol.* **2019**, *140*, 150–158. [[CrossRef](#)]
5. Van der Zee, J. Heating the patient: A promising approach? *Ann. Oncol* **2002**, *13*, 1173–1184. [[CrossRef](#)] [[PubMed](#)]

6. Van der Zee, J.; Vujaskovic, Z.; Kondo, M.; Sugahara, T. Part I. Clinical hyperthermia. The Kadota Fund International Forum 2004—Clinical group consensus. *Int. J. Hyperth.* **2008**, *24*, 111–122. [[CrossRef](#)]
7. Vorst, A.V.; Rosen, A.; Kotsuka, Y. *RF/Microwave Interaction with Biological Tissues*, 1st ed.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2006; pp. 1–330.
8. Kok, H.P.; Cressman, E.N.K.; Ceelen, W.; Brace, C.L.; Ivkov, R.; Grüll, H.; Ter Haar, G.; Wust, P.; Crezee, J. Heating technology for malignant tumors: A review. *Int. J. Hyperth.* **2020**, *37*, 711–741. [[CrossRef](#)] [[PubMed](#)]
9. Dobšiček Trefná, H.; Crezee, H.; Schmidt, M.; Marder, D.; Lamprecht, U.; Ehmann, M.; Hartmann, J.; Nadobny, J.; Gellermann, J.; Van Holthe, N.; et al. Quality assurance guidelines for superficial hyperthermia clinical trials: I. Clinical requirements. *Int. J. Hyperth.* **2017**, *33*, 471–482. [[CrossRef](#)]
10. Cihoric, N.; Tsikkinis, A.; Van Rhoon, G.; Crezee, H.; Abersold, D.M.; Bodis, S.; Beck, M.; Nadobny, J.; Budach, V.; Wust, P.; et al. Hyperthermia-related clinical trials on cancer treatment within the ClinicalTrials.gov registry. *Int. J. Hyperth.* **2015**, *31*, 609–614. [[CrossRef](#)]
11. Van der Zee, J.; Van Rhoon, G.C. Hyperthermia with radiotherapy and with system therapies. In *Brest Cancer*; Veronesi, U., Ed.; Springer: Berlin/Heidelberg, Germany, 2017; pp. 855–862.
12. Lassche, G.; Crezee, J.; Van Herpen, C.M.L. Whole-body hyperthermia in combination with systemic therapy in advanced solid malignancies. *Crit. Rev. Oncol. Hemat.* **2019**, *139*, 67–74. [[CrossRef](#)] [[PubMed](#)]
13. Lee, H.; Park, H.J.; Park, C.-S.; Oh, E.-T.; Choi, B.-H.; Brent, W.; Le, C.K.; Song, C.W. Response of Breast Cancer Cells and Cancer Stem Cells to Metformin and Hyperthermia Alone or Combined. *PLoS ONE* **2014**, *2*, e87979. [[CrossRef](#)]
14. Song, C.W.; Park, H.J.; Lee, C.K.; Griffin, R. Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. *Int. J. Hyperth.* **2005**, *21*, 761–767. [[CrossRef](#)]
15. Goéré, D.; Glehen, O.; Quenet, F.; Guilloit, J.-M.; Bereder, J.-M.; Lorimier, G.; Thibaudeau, E.; Ghouti, L.; Pinto, A.; Tuech, J.-J.; et al. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (Prophylochip–Prodige 15): A randomised, phase 3 study. *Lancet Oncol.* **2020**, *21*, 1147–1154. [[CrossRef](#)]
16. Liang, Z.; Yang, D.; Cheng, W.; Cui, G. Clinical study on microwave deep hyperthermia combined with hepatic artery embolisation and portal vein perfusion in the treatment of advanced liver cancer. *Acta Med. Mediterr.* **2020**, *36*, 465–469.
17. Shabunin, A.V.; Tavobilov, M.M.; Grekov, D.N.; Drozdov, P.A. Combined modality treatment for patients with inoperable colorectal liver metastases. *Sib. J. Oncol.* **2018**, *17*, 34–40. [[CrossRef](#)]
18. Oei, A.L.; Kok, H.P.; Oei, S.B.; Horsman, M.R.; Stalpers, L.J.A.; Franken, N.A.P.; Crezee, J. Molecular and biological rationale of hyperthermia as radio- and chemosensitizer. *Adv. Drug Deliv. Rev.* **2020**, *163*, 84–97. [[CrossRef](#)] [[PubMed](#)]
19. Dobrodeev, A.Y.; Tuzikov, S.A.; Zavyalov, A.A.; Startseva, Z.A. Impact of preoperative thermochemoradiotherapy on surgical outcomes in patients with non-small cell lung cancer. *Vopr. Onkol.* **2020**, *66*, 143–147.
20. Bakker, A.; van der Zee, J.; van Tienhoven, G.; Kok, H.P.; Rasch, C.R.N.; Crezee, H. Temperature and thermal dose during radiotherapy and hyperthermia for recurrent breast cancer are related to clinical outcome and thermal toxicity: A systematic review. *Int. J. Hyperth.* **2019**, *36*, 1023–1038. [[CrossRef](#)]
21. Westermann, A.; Mella, O.; van der Zee, J. Long term survival data of triple modality treatment of stage IIB–III–IVA cervical cancer with combination of radiotherapy, chemotherapy and hyperthermia—An update. *Int. J. Hyperth.* **2012**, *28*, 549–553. [[CrossRef](#)] [[PubMed](#)]
22. Dobšiček Trefná, H.; Schmidt, M.; van Rhoon, G.C. Quality assurance guidelines for interstitial hyperthermia. *Int. J. Hyperth.* **2020**, *36*, 277–294. [[CrossRef](#)]
23. Hildebrandt, B.; Wust, P.; Ahlers, O.; Dieing, A.; Sreenivasa, G.; Kerner, T.; Felix, R.; Riess, H. The cellular and molecular basis of hyperthermia. *Crit. Rev. Oncol. Hemat.* **2002**, *43*, 33–56. [[CrossRef](#)]
24. Roti Roti, J.L. Cellular responses to hyperthermia (40–46 C): Cell killing and molecular events. *Int. J. Hyperth.* **2008**, *24*, 3–15. [[CrossRef](#)] [[PubMed](#)]
25. Van den Tempel, N.; Horsman, M.R.; Kanaar, R. Improving efficacy of hyperthermia in oncology by exploiting biological mechanisms. *Int. J. Hyperth.* **2016**, *32*, 446–454. [[CrossRef](#)]
26. Takahashi, A. Molecular damage: Hyperthermia alone. In *Hyperthermic Oncology from Bench to Bedside*, 1st ed.; Kokura, S., Toshikazu, Y., Takeo, O., Eds.; Springer: Singapore, 2016; pp. 19–32.
27. Elming, P.B.; Sørensen, B.S.; Oei, A.L.; Franken, N.A.P.; Crezee, J.; Overgaard, J.; Horsman, M.R. Hyperthermia: The optimal treatment to overcome radiation resistant hypoxia. *Cancers* **2019**, *11*, 60. [[CrossRef](#)] [[PubMed](#)]
28. Dobšiček, T.H.; Crezee, J.; Schmidt, M.; Marder, D.; Lamprecht, U.; Ehmann, M.; Nadobny, J.; Hartmann, J.; Lomax, N. Quality assurance guidelines for superficial hyperthermia clinical trials. *Strahlenther. Onkol.* **2017**, *193*, 351–366. [[CrossRef](#)] [[PubMed](#)]
29. Gilchrist, R.K.; Medal, R.; Shorey, W.D.; Hanselman, R.C.; Parrott, J.C.; Taylor, C.B. Selective inductive heating of lymph nodes. *Ann. Surg.* **1957**, *146*, 596–606. [[CrossRef](#)] [[PubMed](#)]
30. Johannsen, M.; Gneveckow, U.; Eckelt, L.; Feussner, A.; Waldofner, N.; Scholz, R.; Deger, S.; Wust, P.; Loening, S.A.; Jordan, A. Clinical hyperthermia of prostate cancer using magnetic nanoparticles: Presentation of a new interstitial technique. *Int. J. Hyperth.* **2005**, *21*, 637–647. [[CrossRef](#)]
31. Southern, P.; Pankhurst, Q. Commentary on the clinical and preclinical dosage limits of interstitially administered magnetic fluids for therapeutic hyperthermia based on current practice and efficacy models. *Int. J. Hyperth.* **2017**, *34*, 671–686. [[CrossRef](#)]

32. Maier-Hauff, K.; Ulrich, F.; Nestler, D.; Niehoff, H.; Wust, P.; Thiesen, B.; Orawa, H.; Budach, V.; Jordan, A. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. *J. Neuro-Oncol.* **2011**, *103*, 317–324. [[CrossRef](#)]
33. Kobayashi, T.; Kakimi, K.; Nakayama, E.; Jimbow, K. Antitumor immunity by magnetic nanoparticle-mediated hyperthermia. *Nanomedicine* **2014**, *9*, 1715–1726. [[CrossRef](#)]
34. Petryk, A.A.; Giustini, A.J.; Gottesman, R.E.; Kaufman, P.A.; Hoopes, P.J. Magnetic nanoparticle hyperthermia enhancement of cisplatin chemotherapy cancer treatment. *Int. J. Hyperth.* **2013**, *29*, 845–851. [[CrossRef](#)]
35. Attaluri, A.; Kandala, S.K.; Wabler, M.; Zhou, H.; Cornejo, C.; Armour, M.; Hedayati, M.; Zhang, Y.; DeWeese, T.L.; Herman, C.; et al. Magnetic nanoparticle hyperthermia enhances radiation therapy: A study in mouse models of human prostate cancer. *Int. J. Hyperth.* **2015**, *31*, 359–374. [[CrossRef](#)] [[PubMed](#)]
36. Spirou, S.V.; Costa Lima, S.A.; Bouziotis, P.; Vranješ-Djuric, S.; Efthimiadou, E.K.; Laurenzana, A.; Barbosa, A.I.; Garcia-Alonso, I.; Jones, C.; Jankovic, D.; et al. Recommendations for in vitro and in vivo testing of magnetic nanoparticle hyperthermia combined with radiation therapy. *Nanomaterials* **2018**, *8*, 306. [[CrossRef](#)]
37. Mahmoudi, K.; Bouras, A.; Bozec, D.; Ivkov, R.; Hadjipanayis, C. Magnetic hyperthermia therapy for the treatment of glioblastoma: A review of the therapy's history, efficacy and application in humans. *Int. J. Hyperth.* **2018**, *34*, 1316–1328. [[CrossRef](#)] [[PubMed](#)]
38. Rodrigues, H.F.; Capistrano, G.; Bakuzis, A.F. In vivo magnetic nanoparticle hyperthermia: A review on preclinical studies, low-field nano-heaters, noninvasive thermometry and computer simulations for treatment planning. *Int. J. Hyperth.* **2020**, *37*, 76–99. [[CrossRef](#)]
39. Brezovich, I.A. Low frequency hyperthermia: Capacitive and ferromagnetic thermoseed methods. In *Biological, Physical, and Clinical Aspects of Hyperthermia. Medical Physics Monograph 16*; Paliwal, B., Hetzel, F.W., Dewhurst, M.W., Eds.; American Institute of Physics: College Park, MD, USA, 1988; pp. 82–111.
40. Hergt, R.; Dutz, S. Magnetic particle hyperthermia—Biophysical limitations of a visionary tumour therapy. *J. Magn. Magn. Mater.* **2007**, *311*, 187–192. [[CrossRef](#)]
41. Dutz, S.; Hergt, R. Magnetic nanoparticle heating and heat transfer on a microscale: Basic principles, realities and physical limitations of hyperthermia for tumor therapy. *Int. J. Hyperth.* **2013**, *29*, 790–800. [[CrossRef](#)]
42. Kozissnik, B.; Bohorquez, A.C.; Dobson, J.; Rinaldi, C. Magnetic fluid hyperthermia: Advances, challenges, and opportunity. *Int. J. Hyperth.* **2013**, *29*, 706–714. [[CrossRef](#)] [[PubMed](#)]
43. Dutz, S.; Clement, J.H.; Eberbeck, D.; Gelbrich, T.; Hergt, R.; Muller, R.; Wotschadlo, J.; Zeisberger, M. Ferrofluids of magnetic multicore nanoparticles for biomedical applications. *J. Magn. Magn. Mater.* **2009**, *321*, 1501–1504. [[CrossRef](#)]
44. Dutz, S.; Hergt, R. Magnetic particle hyperthermia—A promising tumour therapy? *Nanotechnology* **2014**, *25*, 452001. [[CrossRef](#)] [[PubMed](#)]
45. Andreu, I.; Natividad, E. Accuracy of available methods for quantifying the heat power generation of nanoparticles for magnetic hyperthermia. *Int. J. Hyperth.* **2013**, *29*, 739–775. [[CrossRef](#)]
46. Garaio, E.; Collantes, J.M.; Plazaola, F.; Garsia, J.A.; Castellanos-Rubio, I.A. Multifrequency electromagnetic applicator with an integrated AC magnetometer for magnetic hyperthermia experiments. *Meas. Sci. Technol.* **2014**, *25*, 115702. [[CrossRef](#)]
47. Coffey, W.T.; Kalmykov, Y.P. Thermal fluctuations of magnetic nanoparticles: Fifty years after Brown. *J. Appl. Phys.* **2010**, *112*, 121301. [[CrossRef](#)]
48. Endelmann, U.M.; Shasha, C.; Teeman, E.; Slabu, I.; Krishnan, K.M. Predicting size-dependent heating efficiency of magnetic nanoparticles from experiment and stochastic Néel-Brown Langevin simulation. *J. Magn. Magn. Mater.* **2019**, *471*, 450–456. [[CrossRef](#)]
49. Bordelon, D.E.; Cornejo, C.; Gruttner, C.; Westphal, F.; DeWeese, T.L.; Ivkov, R. Magnetic nanoparticle heating efficiency reveals magneto-structural differences when characterized with wide ranging and high amplitude magnetic fields. *J. Appl. Phys.* **2011**, *109*, 124904. [[CrossRef](#)]
50. Raouf, I.; Khalid, S.; Khan, A.; Lee, J.; Kim, H.S.; Kim, M.-H. A review on numerical modeling for magnetic nanoparticle hyperthermia: Progress and challenges. *J. Therm. Biol.* **2020**, *91*, 102644. [[CrossRef](#)]
51. Suleman, M.; Riaz, S.; Jalil, R. A mathematical modeling approach toward magnetic fluid hyperthermia of cancer and unfolding heating mechanism. *J. Therm. Anal. Calorim.* **2021**, *146*, 1193–1219. [[CrossRef](#)]
52. Wells, J.; Ortega, D.; Steinhoff, U.; Dutz, S.; Garaio, E.; Sandre, O.; Natividad, E.; Cruz, M.M.; Brero, F.; Southern, P.; et al. Challenges and recommendations for magnetic hyperthermia characterization measurements. *Int. J. Hyperth.* **2021**, *38*, 447–460. [[CrossRef](#)] [[PubMed](#)]
53. Kallumadil, M.; Tada, M.; Nakagawa, T.; Abe, M.; Southern, P.; Pankhurst, Q.A. Suitability of commercial colloids for magnetic hyperthermia. *J. Magn. Magn. Mater.* **2009**, *321*, 1509–1513. [[CrossRef](#)]
54. Hedayatnasab, Z.; Abnisa, F.; Daud, W. Review on magnetic nanoparticles for magnetic nanofluid hyperthermia application. *Mater. Des.* **2017**, *123*, 174–196. [[CrossRef](#)]
55. Barry, J.W.; Bookstein, J.J.; Alksne, J.F. Ferromagnetic embolization. *Radiology* **1981**, *138*, 341–349. [[CrossRef](#)]
56. Akuta, K.; Abe, M.; Kondo, M.; Yoshikawa, T.; Tanaka, Y.; Yoshida, M.; Miura, T.; Nakao, N.; Onoyama, Y.; Yamada, T.; et al. Combined effects of hepatic arterial embolization using degradable starch microspheres (DSM) in hyperthermia for liver cancer. *Int. J. Hyperth.* **1991**, *7*, 231–242. [[CrossRef](#)] [[PubMed](#)]

57. Mauer, C.A.; Renzulli, P.; Baer, H.U.; Mettler, D.; Uhlschmid, G.; Neuenschwander, P.; Suter, U.W.; Triller, J.; Zimmermann, A. Hepatic artery embolization with a novel radiopaque polymer causes extended liver necrosis in pigs due to occlusion of the concomitant portal vein. *J. Hepatol.* **2000**, *32*, 261–268. [[CrossRef](#)]
58. Moroz, P.; Jones, S.K.; Gray, B.N. Status of hyperthermia in the treatment of advanced liver cancer. *J. Surg. Oncol.* **2001**, *77*, 259–269. [[CrossRef](#)]
59. Wilhelm, S.; Tavares, A.J.; Dai, Q.; Ohta, S.; Audet, J.; Dvorak, H.F.; Chan, W.C.W. Analysis of nanoparticle delivery to tumours. *Nat. Rev. Mater.* **2016**, *1*, 16014. [[CrossRef](#)]
60. Moroz, P.; Jones, S.K.; Gray, B.N. Tumor response to arterial embolization hyperthermia and direct injection hyperthermia in a rabbit liver tumor model. *J. Surg. Oncol.* **2002**, *80*, 149–156. [[CrossRef](#)] [[PubMed](#)]
61. Takamatsu, S.; Matsui, O.; Gabata, T.; Kobayashi, S.; Okuda, M.; Ougi, T.; Ikehata, Y.; Nagano, I.; Nagaeet, H. Selective induction hyperthermia following transcatheter arterial embolization with a mixture of nano-sized magnetic particles (ferucarbotran) and embolic materials: Feasibility study in rabbits. *Radiat. Med.* **2008**, *26*, 179–187. [[CrossRef](#)]
62. Attaluri, A.; Seshadri, M.; Mirpour, S.; Wabler, M.; Marinho, T.; Furqan, M.; Zhou, H.; De Paoli, S.; Gruettner, C.; Gilson, W.; et al. Image-guided thermal therapy with dual-contrast magnetic nanoparticle formulation: A feasibility study. *Int. J. Hyperth.* **2016**, *32*, 543–557. [[CrossRef](#)] [[PubMed](#)]
63. Gunvén, P. Liver embolizations in oncology: A review. Part I. Arterial (chemo) embolizations. *Med. Oncol.* **2008**, *25*, 287–296. [[CrossRef](#)]
64. Renard, P.E.L.; Buchegger, F.; Petri-Fink, A.; Bosman, F.; Rufenacht, D.; Hofmann, H.; Doelker, E.; Jordan, O. Local moderate magnetically induced hyperthermia using an implant formed in situ in a mouse tumor model. *Int. J. Hyperth.* **2009**, *25*, 229–239. [[CrossRef](#)]
65. Granov, A.M.; Karelin, M.I.; Granov, D.A.; Tarazov, P.G.; Makovetskaya, K.N. Method for Treatment of Tumors of Parenchymatous Organs Tumors. RU Patent 2065734, 27 August 1996.
66. Karelin, M.I. Substantiation of X-ray Vascular Ferromagnetic Embolization and Local Hyperthermia in Stage IV Renal Cell Carcinoma. Ph.D. Thesis, The Russian Scientific Centre of Radiology and Surgical Technologies, Moscow, Russia, 1998. (In Russian).
67. Granov, A.M.; Davidov, M.I. *Interventional Radiology in Oncology—Ways of Development and Perspectives*; Tumors of Kidney: Ferromagnetic Embolization; LLC Publisher: Saint Petersburg, Russia, 2007; Chapter 8; pp. 289–297. (In Russian)
68. Smolkova, I.S.; Kazantseva, N.E.; Makoveckaya, K.N.; Smolka, P.; Saha, P.; Granov, A.M. Maghemite based silicone composite for arterial embolization hyperthermia. *Mat. Sci. Eng. C-Mater.* **2015**, *48*, 632–641. [[CrossRef](#)] [[PubMed](#)]
69. Makoveckaya, K.N.; Nikolaev, G.A.; Granov, A.M.; Tarazov, P.G.; Kazantseva, N.E.; Smolkova, I.S.; Saha, P.; Treshalina, E.M.; Yakynina, M.N.; Choroshavina, Y.A.; et al. Composition for Embolization and Hyperthermia of Vascular Tumors. RU Patent 26704464 (C1), 23 October 2018.
70. Soetaert, F.; Korangath, P.; Serantes, D.; Fiering, S.; Ivkov, R. Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies. *Adv. Drug Deliv. Rev.* **2020**, *163–164*, 65–83. [[CrossRef](#)] [[PubMed](#)]
71. Maier-Hauff, K.; Rothe, R.; Scholz, R.; Gneveckow, U.; Wust, P.; Thiesen, B.; Feussner, A.; Von Deimling, A.; Waldoefner, N.; Felix, R.; et al. Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: Results of a feasibility study on patients with glioblastoma multiforme. *J. Neuro-Oncol.* **2007**, *81*, 53–60. [[CrossRef](#)]
72. Babo, D.; Robinson, J.K.; Islam, J.; Thurecht, K.J.; Corrie, S.R. Nanoparticle-based medicine: A review of FDA-approved materials and clinical treats to date. *Pharm. Res.* **2016**, *33*, 2373–2387. [[CrossRef](#)] [[PubMed](#)]
73. Granov, A.M.; Muratov, O.V.; Frolov, V.F. Problems in the local hyperthermia of inductively heated embolized tissues. *Theor. Found. Chem. Eng.* **2002**, *36*, 63–66. [[CrossRef](#)]
74. Zhao, L.Y.; Liu, J.Y.; Ouang, W.W.; Li-Dan-Ye, L.L.; Tang, J.T. Magnetic mediated hyperthermia for cancer treatment: Research progress and clinical trials. *Chin. Phys. B* **2013**, *22*, 108104. [[CrossRef](#)]
75. Li, D.; Wang, K.; Wang, X.; Li, L.; Zhao, L.; Tang, J. Magnetic Arterial Embolization Hyperthermia Mediated by Carbonyl Iron Powder for Liver Carcinoma. In Proceedings of the World Congress on Medical Physics and Biomedical Engineering, Beijing, China, 26–31 May 2012.
76. Chikazumi, S.; Graham, C.D. Part VI Domainstructures. In *Physics of Ferromagnetism*, 2nd ed.; Oxford University Press: Oxford, UK, 1999; pp. 387–464.
77. Goodenough, J.B. Summary of losses in magnetic materials. *IEEE Trans. Magn.* **2002**, *38*, 3398–3408. [[CrossRef](#)]
78. Spaldin, N.A. *Magnetic Materials: Fundamentals and Applications*; Cambridge University Press: Cambridge, UK, 2011; pp. 3–270.
79. Dunlop, D.J. The rock magnetism of fine particles. *Phys. Earth Planet. Inter.* **1981**, *26*, 1–26. [[CrossRef](#)]
80. Moskowitz, B.M. Hithhiker’s Guide to Magnetism. In *Environmental Magnetism Workshop (IRM)*; University of Minnesota: Minneapolis, MN, USA, 1991; Volume 279, pp. 1–48.
81. Roberts, A.P.; Almeida, T.P.; Church, N.S.; Harrison, R.J.; Heslop, D.; Li, Y.; Li, J.; Muxworthy, A.R.; Williams, W.; Zhao, X. Resolving the origin of pseudo-single domain magnetic behavior. *J. Geophys. Res.-Sol. Earth* **2017**, *122*, 9534–9558. [[CrossRef](#)]
82. Gatel, C.H.; Bonilla, F.J.; Meffre, A.; Snoeck, E.; Warot-Fonrose, B.; Chaudret, B.; Lacroix, L.M.; Blon, T. Size-Specific Spin Configurations in Single Iron Nanomagnet: From Flower to Exotic Vortices. *Nano Lett.* **2015**, *15*, 6952–6957. [[CrossRef](#)]
83. Coey, J.M.D. Ferromagnetism and exchange. In *Magnetism and Magnetic Materials*, 1st ed.; Cambridge University Press: Cambridge, UK, 2010; pp. 128–174.

84. Krishnan, K.M. Biomedical Nanomagnetism: A Spin through Possibilities in Imaging, Diagnostics, and Therapy. *IEEE Trans. Magn.* **2010**, *46*, 2523–2558. [[CrossRef](#)]
85. Dennis, C.L.; Ivkov, R. Physics of heat generation using magnetic nanoparticles for hyperthermia. *Int. J. Hypertherm.* **2013**, *29*, 715–729. [[CrossRef](#)]
86. Mohapatra, J.; Xing, M.; Beatty, J.; Elkins, J.; Seda, T.; Mishra, S.R.; Liu, J.P. Enhancing the magnetic and inductive heating properties of Fe₃O₄ nanoparticles via morphology control. *Nanotechnology* **2020**, *31*, 275706. [[CrossRef](#)]
87. Nemati, Z.; Alonso, J.; Rodrigo, I.; Das, R.; Garaio, E.; Garcia, J.A.; Orue, I.; Phan, M.H.; Srikanth, H. Improving the heating efficiency of iron oxide nanoparticles by turning their shape and size. *Phys. Chem. C* **2018**, *122*, 2367–2381. [[CrossRef](#)]
88. Das, R.; Alonso, J.; Porshokouh, Z.N.; Kalappattil, V.; Torres, D.; Phan, M.-H.; Garaio, E.; García, J.A.; Sanchez Llamazares, J.L.; Srikanth, H. Tunable High Aspect Ratio Iron Oxide Nanorods for Enhanced Hyperthermia. *Phys. Chem. C* **2016**, *120*, 10086–10093. [[CrossRef](#)]
89. Niraula, G.; Coaquira, J.A.H.; Zoppellaro, G.; Goya, G.F.; Sharma, S.K. Engineering shape anisotropy of Fe₃O₄-Fe₂O₃ hollow nanoparticles for magnetic hyperthermia. *ACS Appl. Nano Mat.* **2021**, *4*, 3148–3158. [[CrossRef](#)]
90. Gonzales-Weimuller, M.; Zeisberger, M.; Krishnan, K.M. Size-dependent heating rates of iron oxide nanoparticles for magnetic fluid hyperthermia. *J. Magn. Magn. Mater.* **2009**, *321*, 1947–1950. [[CrossRef](#)]
91. Castellanos-Rubio, I.; Rodrigo, I.; Munshi, R.; Oihane Arriortua, J.S.; Garitaonandia, A.M.-A.; Plazaola, F.; Iñaki, O.; Pralle, A.; Insausti, M. Outstanding heat loss via nano-octahedra above 20 nm in size: From wustite-rich nanoparticles to magnetite single-crystals. *Nanoscale* **2019**, *11*, 16635–16649. [[CrossRef](#)]
92. Khandhar, A.P.; Ferguson, R.M.; Krishnan, K.M. Monodispersed magnetite nanoparticles optimized for magnetic fluid hyperthermia: Implications in biological systems. *J. Appl. Phys.* **2011**, *109*, 7B310. [[CrossRef](#)]
93. Smolkova, I.S.; Kazantseva, N.E.; Babayan, V.; Vilcakova, J.; Pizurova, N.; Saha, P. The Role of Diffusion-Controlled Growth in the Formation of Uniform Iron Oxide Nanoparticles with a Link to Magnetic Hyperthermia. *Cryst. Growth Des.* **2017**, *17*, 2323–2332. [[CrossRef](#)]
94. Munoz-Menendez, C.; Conde-Leboran, I.; Baldomir, D.; Chubykalo-Fesenko, O.; Serantes, D. Role of size polydispersity in magnetic fluid hyperthermia: Average vs. local infra/over-heating effects. *Phys. Chem. Chem. Phys.* **2015**, *17*, 27812–27820. [[CrossRef](#)]
95. Ota, S.; Takemura, Y. Characterization of Néel and Brownian Relaxations Isolated from Complex Dynamics Influenced by Dipole Interactions in Magnetic Nanoparticles. *J. Phys. Chem. C* **2019**, *123*, 28859–28866. [[CrossRef](#)]
96. Kötitz, R.; Weitschies, W.; Trahms, L.; Brewer, W.; Semmler, W. Determination of the binding reaction between avidin and biotin by relaxation measurements of magnetic nanoparticles. *J. Magn. Magn. Mater.* **1999**, *194*, 62–68. [[CrossRef](#)]
97. Dieckhoff, J.; Eberbeck, D.; Schilling, M.; Ludwig, F. Magnetic-field dependence of Brownian and Néel relaxation times. *J. Appl. Phys.* **2016**, *119*, 043903. [[CrossRef](#)]
98. Hergt, R.; Hieber, R.; Hilger, I.; Kaiser, W.A.; Lapatnikov, Y.; Margel, S.; Richter, U. Maghemite nanoparticles with very high AC-losses for application in RF-magnetic hyperthermia. *J. Magn. Magn. Mater.* **2004**, *270*, 345–357. [[CrossRef](#)]
99. Bishop, K.J.M.; Wilmer, C.E.; Soh, S.; Grzybowski, B.A. Nanoscale forces and their uses in self-assembly. *Small* **2009**, *5*, 1600–1630. [[CrossRef](#)]
100. Lalatonne, Y.; Richardi, J.; Pileni, M.P. Van der Waals versus dipolar forces controlling mesoscopic organizations of magnetic nanocrystals. *Nat. Mater.* **2004**, *3*, 121–125. [[CrossRef](#)] [[PubMed](#)]
101. Serantes, D.; Baldomir, D. Nanoparticle Size Threshold for Magnetic Agglomeration and Associated Hyperthermia Performance. *Nanomaterials* **2021**, *11*, 2786. [[CrossRef](#)]
102. Held, G.A.; Grinstein, G.; Doyle, H.; Sun, S.H.; Murray, C.B. Competing interactions in dispersions of superparamagnetic nanoparticles. *Phys. Rev. B* **2001**, *64*, 124081–124084. [[CrossRef](#)]
103. Scholten, P.C.; Tjaden, D.L.A. Mutual attraction of superparamagnetic particles. *J. Colloid. Interf. Sci* **1980**, *73*, 254–255. [[CrossRef](#)]
104. Barman, A.; Mondal, S.; Sahoo, S.; De, A. Magnetization dynamics of nanoscale magnetic materials: A perspective. *J. Appl. Phys.* **2020**, *128*, 170901. [[CrossRef](#)]
105. Mørup, S.; Hansen, M.F.; Frandsen, C. Magnetic Nanoparticles. In *Comprehensive Nanoscience and Technology*, 2nd ed.; David, L., Andrews, G.D., Scholes, G.P., Eds.; Academic Press: Cambridge, MA, USA, 2011; pp. 437–491.
106. Schaller, V.; Wahnström, G.; Sanz-Velasco, A.; Enoksson, P.; Johansson, C. Monte Carlo simulation of magnetic multi-core nanoparticles. *J. Magn. Magn. Mater.* **2009**, *321*, 1400–1403. [[CrossRef](#)]
107. Smolková, I.S.; Kazantseva, N.E.; Babayan, V.; Smolka, P.; Parmar, H.; Vilčáková, J.; Schneeweiss, O.; Pizurová, N. Alternating magnetic field energy absorption in the dispersion of iron oxide nanoparticles in a viscous medium. *J. Magn. Magn. Mater.* **2015**, *374*, 508–515. [[CrossRef](#)]
108. Smolková, I.S.; Kazantseva, N.E.; Vitková, L.; Babayan, V.; Vilčáková, J.; Smolka, P. Size dependent heating efficiency of multicore iron oxide particles in low-power alternating magnetic fields. *Acta Phys. Pol. A* **2017**, *131*, 663–665. [[CrossRef](#)]
109. Bender, F.; Fock, J.; Frandsen, C.; Hansen, F.M.; Balceris, C.; Ludwig, F.; Posth, O.; Wetterskog, E.; Bogart, L.K.; Southern, P.; et al. Relating magnetic properties and high hyperthermia performance of iron oxide nanoflowers. *J. Phys. Chem. C* **2018**, *122*, 3068–3077. [[CrossRef](#)]
110. Dutz, S. Are magnetic nanoparticles promising candidates for biomedical applications? *IEEE Trans. Magn.* **2016**, *52*, 0200103. [[CrossRef](#)]

111. Ovejero, J.G.; Cabrera, D.; Carrey, J.; Valdivielso, T.; Salas, G.; Teran, F.J. Effects of inter- and intra-aggregate magnetic dipolar interactions on the magnetic heating efficiency of iron oxide nanoparticles. *Phys. Chem. Chem. Phys.* **2016**, *18*, 10954–10963. [[CrossRef](#)] [[PubMed](#)]
112. Landi, G.T. Role of dipolar interaction in magnetic hyperthermia. *Phys. Rev. B* **2014**, *89*, 011403. [[CrossRef](#)]
113. Coral, D.F.; Zelis, P.M.; Marciello, M.; Morales, M.D.; Craievich, A.A.; Sanchez, F.H.; Van Raap, M.B.F. Effect of nanoclustering and dipolar interactions in heat generation for magnetic hyperthermia. *Langmuir* **2016**, *32*, 1201–1213. [[CrossRef](#)]
114. Ivanov, A.O.; Kantorovich, S.S.; Elfimova, E.A.; Zverev, V.S.; Sindt, J.O.; Camp, P.J. The influence of interparticle correlations and self-assembly on the dynamic initial magnetic susceptibility spectra of ferrofluids. *J. Magn. Magn. Mater.* **2017**, *431*, 141–144. [[CrossRef](#)]
115. Branquinho, L.C.; Carriao, M.S.; Costa, A.S.; Zufelato, N.; Sousa, M.H.; Miotto, R.; Ivkov, R.; Bakuzis, A.F. Effect of magnetic dipolar interactions on nanoparticle heating efficiency: Implications for cancer hyperthermia. *Sci. Rep.* **2013**, *3*, 2887. [[CrossRef](#)]
116. Usov, N.A.; Serebryakova, O.N.; Tarasov, V.P. Interaction effects in assembly of magnetic nanoparticles. *Nanoscale Res. Lett.* **2017**, *12*, 489–497. [[CrossRef](#)]
117. Usov, N.A.; Nesmeyanov, M.S.; Tarasov, V.P. Magnetic vortices as efficient nano heaters in magnetic nanoparticle hyperthermia. *Sci. Rep.* **2018**, *8*, 1224–1233. [[CrossRef](#)]
118. Pourmiri, S.; Tzitzios, V.; Hadjipanayis, G.C.; Meneses Brassea, B.P.; El-Gendyet, A.A. Magnetic properties and hyperthermia behavior of iron oxide nanoparticle clusters. *AIP Adv.* **2019**, *9*, 125033–125038. [[CrossRef](#)]
119. Jonasson, C.H.; Schaller, V.; Zeng, L.; Olsson, E.; Frandsen, C.; Castro, A.; Nilsson, L.; Bogart, L.K.; Southern, P.; Pankhurst, Q.A.; et al. Modelling the effect of different core sizes and magnetic interactions inside magnetic nanoparticles on hyperthermia performance. *J. Magn. Magn. Mater.* **2019**, *477*, 198–202. [[CrossRef](#)]
120. Lee, J.H.; Jang, J.T.; Choi, J.S.; Moon, S.H.; Noh, S.H.; Kim, J.W.; Kim, J.G.; Kim, I.S.; Park, K.I.; Cheon, J. Exchange-coupled magnetic nanoparticles for efficient heat induction. *Nat. Nanotechnol.* **2011**, *6*, 418–422. [[CrossRef](#)] [[PubMed](#)]
121. López-Ortega, A.; Estrader, M.; Salazar-Alvarez, G.; Roca, A.G.; Nogués, J. Applications of exchange coupled bi-magnetic hard/soft and soft/hard magnetic core/shell nanoparticles. *Phys. Rep.* **2015**, *553*, 1–32. [[CrossRef](#)]
122. Phan, M.-H.; Alonso, A.; Khurshid, H.; Lampen-Kelley, P.; Chandra, S.; Repa, K.S.; Nemati, Z.; Das, R.; Iglesias, Ó.; Srikanthet, H. Exchange bias effects in iron oxide-based nanoparticle systems. *Nanomaterials* **2016**, *6*, 221. [[CrossRef](#)]
123. Balaev, D.A.; Semenova, S.V.; Dubrovskii, A.A.; Krasikova, A.A.; Popkova, S.I.; Yakushkin, S.S.; Kirillov, V.L.; Mart'yanov, O.N. Synthesis and magnetic properties of the core-shell Fe₃O₄/CoFe₂O₄ nanoparticles. *Phys. Solid State* **2020**, *62*, 285–290. [[CrossRef](#)]
124. Rösch, J.; Keller, F.S.; Kaufman, J.A. The birth, early years, and future of interventional radiology. *J. Vasc. Interv. Radiol.* **2003**, *14*, 841–853. [[CrossRef](#)]
125. Muller, A.; Rouvière, O. Renal artery embolization-indications, technical approaches and outcomes. *Nat. Rev. Nephrol.* **2015**, *11*, 288–301. [[CrossRef](#)]
126. Le Renard, P.E.; Buchegger, F.; Petri-Fink, A.; Hofmann, H.; Doelker, E.; Jordan, O. Formulations for local, magnetically mediated hyperthermia treatment of solid tumors, and Dendritic nanostructures grown in hierarchical branched pores. In *Advances in Nanotechnology*, 1st ed.; Bartul, Z., Trenor, J., Eds.; Nova Science Publishes Inc.: New York, NY, USA, 2014; Volume 12, pp. 1–93, 123–155.
127. Poursaid, A.; Jensen, M.M.; Huoc, E.; Ghandehari, H. Polymeric materials for embolic and chemoembolic applications. *J. Control. Release* **2016**, *240*, 414–433. [[CrossRef](#)]
128. Xu, R.; Yu, H.; Zhang, M.; Chen, Z.; Wang, W.; Teng, G.; Ma, J.; Sun, X.; Gu, N. Three-dimensional model for determining inhomogeneous thermal dosage in a liver tumor during arterial embolization hyperthermia incorporating magnetic nanoparticles. *IEEE Trans. Magn.* **2009**, *45*, 3085–3091.
129. Sun, H.; Xu, L.; Fan, T.; Zhan, H.; Wang, H.; Zhou, Y.; Yang, R.-J. Targeted hyperthermia after selective embolization with ferromagnetic nanoparticles in a VX2 rabbit liver tumor model. *Int. J. Nanomed.* **2013**, *8*, 3795–3804. [[CrossRef](#)]
130. Idee, J.M.; Guiu, B. Use of Lipiodol as a drug delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: A review. *Crit. Rev. Oncol. Hemat.* **2013**, *88*, 530–549. [[CrossRef](#)]
131. Cruise, G.M.; Constant, M.J.; Keely, E.M.; Greene, R.; Harris, C. Polymeric Treatment Composition. WO 2014062696 A1, 24 April 2014.
132. Kwabena Kan-Dapaah, K.; Rahbar, N.; Soboyejo, W. Implantable magnetic nanocomposites for the localized treatment of breast cancer. *J. Appl. Phys.* **2014**, *116*, 233505. [[CrossRef](#)]
133. Moroz, P.; Pardoe, H.; Jones, S.K.; St Pierre, T.G.; Song, S.; Gray, N.B. Arterial embolization hyperthermia: Hepatic iron particle distribution and its potential determination by magnetic resonance imaging. *Phys. Med. Biol.* **2002**, *47*, 1591–1602. [[CrossRef](#)] [[PubMed](#)]
134. Margolis, J.M. Elastomeric Materials and Processes. In *Handbook of Plastics, Elastomers and Composites*, 3rd ed.; Harper, C.A., Ed.; Oxford University Press: New York, NY, USA, 1996; Chapter 3; p. 844.
135. Smolkova, I.S.; Kazantseva, N.E.; Parmar, H.; Babayan, V.; Smolka, P.; Saha, P. Correlation between coprecipitation reaction course and magneto-structural properties of iron oxide nanoparticles. *Mater. Chem. Phys.* **2015**, *155*, 178–190. [[CrossRef](#)]
136. Kavanagh, G.M.; Ross-Murphy, S.B. Rheological characterization of polymer gels. *Prog. Polym. Sci.* **1998**, *23*, 533–562. [[CrossRef](#)]

137. Shen, W.; Zhang, J. Modeling and numerical simulation of bioheat transfer and biomechanics in soft tissue. *Math. Comput. Model.* **2005**, *41*, 1251–1265. [[CrossRef](#)]
138. Treshalina, H.M.; Yakunina, M.N.; Makovetskay, K.N.; Stangevskiy, A.A. Dynamics of tumor growth under the action of the new nano-ferrimagnetic nanoembosil with transarterial introduction. *Vopr. Onkol.* **2020**, *66*, 578–582.
139. Treshalina, H.M.; Zhukova, O.S.; Gerasimova, G.K. Guidelines for preclinical study of the antitumour activity of drugs. In *Manual for Conducting Preclinical Studies of Drugs*; Mironov, A.N., Bunatyan, N.D., Eds.; Grif and K: Moscow, Russia, 2012; Chapter 39; pp. 640–654.
140. Thomas, C.; Polin, L.; Lo Russo, P.; Valeriote, F.; Panchapor, C.; Pugh, S. In vivo methods for screening and preclinical testing. In *Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval*; Teicher, B.A., Andrews, P.A., Eds.; Humana Press: Totowa, NJ, USA, 2004; Chapter 6; pp. 99–123.
141. Nair, A.B.; Jacob, S. A simple practice guide for dose conversion between animals and human. *J. Basic Clin. Pharm.* **2016**, *7*, 27–31. [[CrossRef](#)]
142. Xia, H.; Li, F.; Hu, X.; Park, W.; Wang, S.; Jang, Y.; Du, Y.; Baik, S.; Cho, S.; Kang, T.; et al. pH-sensitive Pt nanoclusters assembly overcomes cisplatin resistance and heterogeneous stemness of hepatocellular carcinoma. *ACS Cent. Sci.* **2016**, *2*, 802–811. [[CrossRef](#)]
143. Goldman, A. *Mordent Ferrite Technology*; Springer Science & Business Media: Berlin/Heidelberg, Germany, 2006.
144. Mirković, M.; Radović, M.; Stanković, D.; Milanović, Z.; Janković, D.; Matović, M.; Jeremić, M.; Antić, B.; Vranješ-Đurić, S. ^{99m}Tc-Bisphosphonate-Coated magnetic nanoparticles as potential theranostic nanoagent. *Mat. Sci. Eng. C* **2019**, *102*, 123–133. [[CrossRef](#)]
145. Abu-Bakr, A.F.; Iskakova, L.Y.; Zubarev, A.Y. Heat exchange within the surrounding biological tissue during magnetic hyperthermia. *Math. Model. Eng. Probl.* **2020**, *7*, 196–200. [[CrossRef](#)]